|
Brain Dysfunction Discussion Group
This highly interdisciplinary discussion group focuses on timely issues in neuroscience, bringing together scientists working in basic neural systems, neurodegenerative diseases, and psychiatric disorders.
Meetings concentrate on cell death, mitochondrial function, protein misfolding, glial cell function, motor neuron deficiencies, synaptic integrity, and other physiological functions as they relate to the central nervous system. There is a particular emphasis on the mechanisms underlying neurodegenerative and psychiatric diseases including but not limited to autism, Alzheimer’s disease, demyelinating diseases, Parkinson’s disease, Huntington’s disease, schizophrenia, and depression. Meetings feature talks covering basic, clinical, and translational aspects of research.
Past Events
Monday, May 6, 2013 | 8:15 AM - 4:00 PM
Speakers: Kurt R. Brunden (University of Pennsylvania), Grant J. Carr (AMRI), Gabriela Chiosis (Memorial Sloan-Kettering Cancer Center), Jerold Chun (The Scripps Research Institute), Bonnie M. Davis (Synaptec), Chad Dickey (University of South Florida), Frank E. Koehn (Pfizer Global R&D), David J. Newman (National Cancer Institute, NIH), Salvatore Oddo (University of Texas Health Science Center, San Antonio), Giulio Maria Pasinetti (Mount Sinai School of Medicine)
Alzheimer's disease may benefit from the novel chemistries found in natural products. This conference explores drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs.
Wednesday, March 20, 2013 | 12:00 PM - 4:00 PM
Speakers: Ben Philpot (University of North Carolina, Chapel Hill), Tim Roberts (The Children's Hospital of Philadelphia), Stephan Sanders (Yale University School of Medicine), Laurence Tecott (University of California, San Francisco), Paul Wang (Seaside Therapeutics)
Explore recent breakthroughs in early detection of autism and promising therapeutic interventions. This symposium features presents updates on the genetic landscape, the use of mouse models to explore behavior and potential therapeutic biomarkers.
Thursday, November 29, 2012 | 12:00 PM - 4:15 PM
Organizers: Rudolph Tanzi (Massachusetts General Hospital and Harvard Medical School), George Zavoico (MLV & Co.), Jennifer Henry (The New York Academy of Sciences)
Speakers: Robert A. Cherny (The Florey Institute of Neuroscience and Mental Health, Australia), Steven M. Hersch (Massachusetts General Hospital and Harvard Medical School), Rudolph Tanzi (Massachusetts General Hospital and Harvard Medical School), Dan Tardiff (Whitehead Institute for Biomedical Research)
Transition metals including Fe, Zn and Cu affect neurotransmission and are implicated in Parkinson's, Huntington's and Alzheimer's diseases. This symposium explores mechanisms for restoring the physiologic balance of transition metals in the brain.
Friday, May 4, 2012 | 9:00 AM - 5:00 PM
Organizers: Howard Fillit (Alzheimer's Drug Discovery Foundation) and Jennifer Henry (The New York Academy of Sciences)
Vascular alterations are both a cause and a consequence of neuronal loss. This conference presents current knowledge on the vascular connection to Alzheimer's pathogenesis and highlights novel approaches to intervention for therapeutic development.
Wednesday, September 28, 2011 | 1:00 PM - 5:00 PM
Speakers: Paul D. Coleman (Sun Health Research Center), Yitshak Francis (Columbia University Medical Center), J. David Sweatt (University of Alabama at Birmingham), Li-Huei Tsai (Massachusetts Institute of Technology) and Benjamin Tycko (Columbia University).
This symposium will review current knowledge on the contribution of epigenetic modifications in the initiation and progress of Alzheimer’s disease with the goal of advancing basic knowledge and identifying new areas for therapeutic interventions.
Wednesday, May 18, 2011 | 9:00 AM - 4:00 PM
Organizers: Howard M. Fillit (Alzheimer's Drug Discovery Foundation) and Sonya Dougal (The New York Academy of Sciences)
This conference will provide an overview of the mechanisms of synaptic plasticity in normal aging and in neurodegenerative disease, and outline therapeutic strategies to preserve vital neural connections.
Tuesday, February 8, 2011 | 1:00 PM - 5:30 PM
Keynote Speaker: John H. Krystal, MD (Yale University School of Medicine) and Darrel A. Regier, MD, MPH (American Psychiatric Association)
This meeting will examine the current relationship between basic research and psychiatric diagnosis and the issues that need to be addressed for these two perspectives to more effectively inform one another.
Wednesday, December 1, 2010 | 1:00 PM - 5:00 PM
Speakers: Brett Abrahams (Albert Einstein College of Medicine), Ami Klin (Yale University), Tim Roberts (The Children's Hospital of Philadelphia), Matthew State (Yale University School of Medicine), and Paul Wang (Seaside Therapeutics)
This meeting will feature researchers striving to advance our understanding of the causes of ASD and to improve the ability for early diagnosis through genetic, neuroimaging, and behavioral techniques.
Thursday, May 13, 2010 | 8:30 AM - 5:00 PM
Organizers: Howard M. Fillit (Alzheimer's Drug Discovery Foundation) and Sonya Dougal (The New York Academy of Sciences)
Please join us for a critical discussion of potential drug therapeutics for mitochondrial dysfunction in Alzheimer's disease.
Tuesday, December 15, 2009 | 1:00 PM - 5:00 PM
Speakers: Haim Einat (University of Minnesota), Rif S. El-Mallakh (University of Louisville School of Medicine), Todd Gould (University of Maryland School of Medicine), Alexander B. Niculescu, III (Indiana University School of Medicine)
This symposium will highlight new developments in Bipolar disorder models and biomarker identification, and will reveal how these new strategies can further our understanding of the disease and our ability to identify new therapies.
Tuesday, October 27, 2009 | 1:00 PM - 5:00 PM
Speakers: Suzanne M. de la Monte (Brown Medical School), William L. Klein (Northwestern University), José A. Luchsinger (Columbia University), Mark Mattson (National Institute on Aging, NIH)
Alzheimer’s disease (AD) has been called Type 3 diabetes, unique to the brain; others suggest that diabetes is a risk factor for AD. This symposium will discuss the significance of cerebral metabolic disturbances in Alzheimer's disease.
Steering Committee
|
Columbia University
|
Alzheimer's Drug Discovery Foundation
|
|
Ellison Medical Foundation |
Sanofi-Aventis
|
|
Simons Foundation
|
|
Sponsors
The Brain Dysfunction Discussion Group is proudly supported by:
Mission Partner support for the Frontiers of Science program provided by 
Get more information about how you can sponsor a discussion group.
|
|